Live Chat
Today's Hours: 8:00am - 8:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Eric Raymond, Sandrine Faivre, Philippe Ruszniewski editors.
    Summary: This book pursues a multidisciplinary approach, presenting chapters with updated information on various aspects of treatment for patients with neuroendocrine tumors. Authors have been selected from expert centers in Europe and the United States. The goal of this book is to comprehensively summarize recent data and provide inspiring ideas to optimize the care of patients with neuroendocrine tumors. Neuroendocrine tumors are fascinating multifaceted diseases that can primarily localize in many organs with various presentations. These tumors are rare but their increasing incidence renders likely that physicians caring for cancers may have either already faced or may be certainly exposed to diagnose and/or treat a patient with neuroendocrine tumors. Over the last years, novel therapeutic options have emerged for neuroendocrine tumors, profoundly challenging practices that had previously been the standards for decades. These include - but are not limited to - somatostatin analogues, targeted therapies such as tyrosine kinase and mTOR inhibitors, antiangiogenic compounds, but also peptide-receptor targeted therapy or radioembolization. This changing field has generated novel treatment algorithms to guide medical decisions. To better understand and handle the multidisciplinary approaches that are required for optimizing the care of neuroendocrine tumor patients, physicians are now looking for references from experts and comprehensive reviews summarizing current knowledge on treatments for patients with neuroendocrine tumors.

    Contents:
    Scintigraphy in Endocrine Tumors of the Gut
    Profiling the PI3K/Akt/Mtor Intracellular Pathway in Neuroendocrine Tumors
    Relevance of Angiogenesis in Neuroendocrine Tumors
    Advances with Somatostatin Analogues in Neuroendocrine Tumors: The Promise of Radionuclides in Neuroendocrine Tumors
    Streptozotocin-Based Chemotherapy is not History in Neuroendocrine Tumors
    Place of Surgical Resection in the Treatment Strategy in Neuroendocrine Tumors
    Endoscopic Resection of Gastrointestinal Neuroendocrine Tumors
    Liver-Targeting Therapies in Neuroendocrine Tumors
    Inhibition of Mtor in Neuroendocrine Tumors of the Digestive Tract
    Sunitinib in Pancreatic Neuroendocrine Tumors
    Clinical Management of Targeted Therapies in Neuroendocrine Tumors
    Imaging Tumor Response to Angiogenesis Inhibitors in Neuroendocrine Tumors
    Resistance to Targeted Therapies in Neuroendocrine Tumors
    New Anticancer Agents in Neuroendocrine Tumors
    Management of Symptoms and Patient Related Outcome Optimization in Neuroendocrine Tumors of the Digestive Tract
    Clinical Approaches of Emergencies in NET.
    Digital Access Springer 2014
  • Article
    Liew FY, Chan-Liew WL.
    Eur J Immunol. 1978 Mar;8(3):168-71.
    An antigen-specific suppressor factor for delayed-type hypersensitivity (DTH) to sheep red blood cells (SRBC) in mice is described. Lymph node cells and spleen cells from mice injected intravenously with 1 x 10(9) SRBC 4 days previously were incubated in vitro for 48 h in culture medium. Supernatant obtained from the culture inhibited the induction of DTH to SRBC in normal mice. It also suppressed the expression of DTH in presensitized mice. The suppression is specific as the suppressor factor had no effect on the DTH to noncross-reacting antigen, chicken red blood cells. Treatment of the spleen cells with anti-theta serum and complement prevented the production of the suppressor factor, whereas treatment with anti-Ig serum and complement had no effect. Suppressor factor produced by H-2k mice suppressed the DTH in H-2b mice. The factor thus seems to act across the H-2 barrier. The suppressor factor was not removed by adsorption with goat anti-mouse immunoglobulin immunoadsorbent, but could be adsorbed by SRBC. It was stable at 56 degrees C for 1 h, but was partially inactivated by freezing and thawing. The factor has a molecular weight of less than 35 000 daltons.
    Digital Access Access Options